{"url":"https://newsforagent.com/news/2026-10-16/techcyte-aignostics-ngs-macrodissection-workflow","markdown_url":"https://newsforagent.com/news/2026-10-16/techcyte-aignostics-ngs-macrodissection-workflow.md","title":"Techcyte Adds Aignostics AI Macrodissection to Fusion AP","headline":"Techcyte and Aignostics Launch AI-Guided NGS Macrodissection Workflow on Fusion AP","description":"Techcyte and Aignostics launched an AI-guided macrodissection workflow for NGS preparation on Techcyte Fusion AP, using HETA Tumor Cellularity.","section":"Product Launches","published_at":"2026-10-16T15:15:38+00:00","modified_at":"2026-10-16T15:15:38+00:00","author":"News Desk","key_takeaways":["Techcyte and Aignostics launched an AI-guided macrodissection workflow for next-generation sequencing preparation on Techcyte Fusion AP.","The workflow uses Aignostics' HETA Tumor Cellularity, part of the HETA Clinical product family, to highlight tumor-rich regions on digital H&E slides.","Techcyte Fusion AP and HETA Tumor Cellularity are for Research Use Only in the United States and are not for diagnostic use."],"companies":[{"name":"Techcyte","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00007be/techcyte","website":"https://www.techcyte.com"}],"source":{"publisher":"EIN Presswire","title":"Techcyte, Aignostics launch AI-guided NGS macrodissection workflow","url":"https://www.einnews.com/article/950152808/live"},"other_sources":[],"tags":["Product Launches","Techcyte"],"body_markdown":"[Techcyte](https://akta.pro/company-profiles/00007be/techcyte) and Aignostics launched an AI-guided macrodissection workflow for next-generation sequencing preparation on Techcyte Fusion AP, using Aignostics' HETA Tumor Cellularity, the companies said on October 16, 2026. The announcement came ahead of Pathology Visions 2026 in San Diego, according to [EIN Presswire](https://www.einnews.com/article/950152808/live).\n\n## How the Fusion AP Macrodissection Workflow Works\n\nWithin Fusion AP, pathologists review a digital H&E slide with cell classification and tissue segmentation overlays from HETA Tumor Cellularity. The overlays highlight candidate tumor-rich regions, and pathologists can adjust tumor cellularity thresholds and refine scraping boundaries based on the intended test requirements. The system updates estimated tumor cellularity, scrapable surface area, tumor cell count, and total cell count as regions change.\n\nAfter a pathologist confirms a region, a slide-sized view helps a histotechnician align the corresponding physical unstained slide with the selected boundaries, and the histotechnician then uses the view as a guide for scraping. HETA Tumor Cellularity is part of Aignostics' HETA Clinical product family, which Aignostics launched on October 16, 2026, according to PR Newswire, describing pan-cancer AI products for pathology workflows including slide quality, tumor detection, mitosis counting, and tumor cellularity, aimed at reducing failed molecular tests by 10-20% due to insufficient tumor content. Techcyte Fusion AP and Aignostics' HETA Tumor Cellularity are for Research Use Only in the United States and are not for diagnostic use.\n\n## Techcyte's Funding and Platform Scale\n\nTechcyte closed a $15 million capital raise in April 2026 led by Van Tuyl Companies with participation from existing investors Zoetis and Mayo Clinic, according to akta.pro [company records](https://akta.pro/company-data), providing access to Mayo Clinic's Safe Harbor dataset of 17M+ de-identified slides for AI training. The same records show Techcyte achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 for the Fusion AP digital pathology platform in March 2026, enabling commercialization across the European Economic Area. Techcyte analyzed nearly 9 million digital scans across all platforms in 2025, the records show.\n\n## Earlier Techcyte Integrations\n\nTechcyte is developing an integration with Aignostics and Epredia to connect its Fusion AP platform with the 3DHISTECH TMA Grand Master, enabling automated coring of confirmed regions of interest from digital slides, EIN Presswire reported in October 2026. NovoPath and Techcyte announced an integration between their platforms in October 2026, linking Techcyte Fusion whole-slide images and AI analysis to NovoPath LIS cases, EIN Presswire reported. Techcyte and elea announced in August 2026 that eleaDNAi, an AI-native pathology reporting tool, is now available within Techcyte Fusion, EIN Presswire reported.\n\n## Pathology Visions 2026 Demonstrations\n\nTechcyte will show the workflow at booth 410 at Pathology Visions 2026 in San Diego, and Aignostics will show it at booth 311. Pathology teams can evaluate the workflow in person at the conference.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}